Intra-Cellular Bipolar Drug Shows "Significant" Benefit in Depressive Episodes

New York-based Intra-Cellular Therapies published the results of its Study 404 phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.